-
公开(公告)号：US09040111B2
公开(公告)日：2015-05-26
申请号：US13729630
申请日：2012-12-28
申请人： JAPAN STENT TECHNOLOGY CO., LTD. , TOKAI UNIVERSITY EDUCATIONAL SYSTEM , TOYO ADVANCED TECHNOLOGIES CO., LTD. , Hiroo Iwata
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.
摘要翻译： 一种制备支架的方法，包括制备含有组合物的溶液，所述组合物包含可生物降解的聚合物和包括不抑制内皮细胞增殖的阿格曲班的血管内膜增生抑制剂，聚合物的重量组成比 至血管内膜增生抑制剂的浓度在8:2至3:7的范围内，该组合物溶于选自低级烷基酮和甲醇的混合物，低级烷基酯和甲醇的混合物的溶剂中 或低级卤代烃和甲醇的混合物; 涂覆具有外表面和内表面的具有涂覆在表面上的类金刚石薄片的圆柱形构造的支架主体的至少外表面; 并且在涂覆之后，除去溶剂以完成第一涂层。
-
公开(公告)号：US08641756B2
公开(公告)日：2014-02-04
申请号：US13492290
申请日：2012-06-08
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
IPC分类号： A61F2/82
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
公开(公告)号：US08409272B2
公开(公告)日：2013-04-02
申请号：US12733460
申请日：2008-09-03
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
IPC分类号： A61F2/82
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
公开(公告)号：US20100198344A1
公开(公告)日：2010-08-05
申请号：US12733460
申请日：2008-09-03
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
IPC分类号： A61F2/82 , B05D3/00 , A61K31/4709 , A61P7/00
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
公开(公告)号：US08968392B2
公开(公告)日：2015-03-03
申请号：US13561828
申请日：2012-07-30
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.
摘要翻译： 一种抑制血管内膜增生的方法，包括：将支架放置在血管内，所述支架具有圆柱形构造的支架主体，其外表面和内表面具有涂覆在其上的金刚石状薄膜，第一涂层涂层 至少支架体的外表面，第一涂层由包含生物可降解聚合物和一种血管内膜增生抑制剂的第一组合物制成，其包含不抑制内皮细胞增殖的阿加曲班，其重量组成比 血管内膜增生抑制剂的聚合物在8:2至7:3的范围内，以及第二涂层; 并使阿加曲班从支架释放，从而抑制血管内膜增生而不抑制内皮细胞的增殖。
-
公开(公告)号：US20130018455A1
公开(公告)日：2013-01-17
申请号：US13561828
申请日：2012-07-30
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.
摘要翻译： 一种抑制血管内膜增生的方法，包括：将支架放置在血管内，所述支架具有圆柱形构造的支架主体，其外表面和内表面具有涂覆在其上的金刚石状薄膜，第一涂层涂层 至少支架体的外表面，第一涂层由包含生物可降解聚合物和一种血管内膜增生抑制剂的第一组合物制成，其包含不抑制内皮细胞增殖的阿加曲班，其重量组成比 血管内膜增生抑制剂的聚合物在8:2至7:3的范围内，以及第二涂层; 并使阿加曲班从支架释放，从而抑制血管内膜增生而不抑制内皮细胞的增殖。
-
公开(公告)号：US20100249914A1
公开(公告)日：2010-09-30
申请号：US12801307
申请日：2010-06-02
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.032 秒)
